Eurocine Vaccines advances the development of commercial manufacturing method and updates time plan
In connection with the procurement of contract manufacturer for the active protein in the chlamydia vaccine candidate, Eurocine Vaccines AB (“Eurocine Vaccines” or the “Company”) has, already at this stage, decided to develop a manufacturing method, which is suitable for the manufacture of vaccines on an industrial scale. In connection with the decision, the Company has updated the time plan.The decision to develop an industrial method for the manufacture of the vaccine at an early stage means that the investment in future work, such as toxicological studies and all clinical studies in